Current Cardiology Reports

, Volume 4, Issue 6, pp 494–500 | Cite as

Dyslipidemia of the metabolic syndrome

  • Giacomo Ruotolo
  • Barbara V. Howard

Abstract

The three major components of dyslipidemia associated with the metabolic syndrome are increased fasting and post-prandial triglyceride-rich lipoproteins (TRLs), decreased high-density lipoprotein (HDL), and increased small, dense low-density lipoprotein (LDL) particles. Insulin resistance and compensatory hyperinsulinemia lead to overproduction of very low-density lipoprotein particles. A relative deficiency of lipoprotein lipase, an insulin-sensitive enzyme, is partly responsible for the decreased clearance of fasting and postprandial TRLs, and the decreased production of HDL particles. The resulting increased concentration of cholesteryl ester-rich fasting and postprandial TRLs is the central lipoprotein abnormality of the metabolic syndrome. The increase of small, dense LDL particles, and decrease of large, buoyant HDL particles are consequential events. All these lipoprotein defects contribute largely to the increased cardiovascular disease risk in individuals with insulin resistance. Peroxisome proliferator-activated receptor (PPAR)α, PPARγ, and PPARδ agonists seem to improve dyslipidemia of the metabolic syndrome by regulating the expression of important genes involved in the deranged lipoprotein metabolism associated with insulin resistance.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.CrossRefGoogle Scholar
  2. 2.
    Castelli WP: Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992, 70:3H-9H.PubMedCrossRefGoogle Scholar
  3. 3.
    Balkau B, Eschwege E: Insulin resistance: an independent risk factor for cardiovascular disease? Diabetes Obesity Metab 1999, 1(Suppl 1):S23-S31.CrossRefGoogle Scholar
  4. 4.
    Lamarche B, Tchernof A, Mauriege P, et al.: Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998, 279:1955–1961.PubMedCrossRefGoogle Scholar
  5. 5.
    Manolio TA, Savage PJ, Burke GL, et al.: Association of fasting insulin with blood pressure and lipids in young adults. The CARDIA study. Arteriosclerosis 1990, 10:430–436.PubMedGoogle Scholar
  6. 6.
    Haffner SM, Mykkanen L, Stern MP, et al.: Relationship of proinsulin and insulin to cardiovascular risk factors in nondiabetic subjects. Diabetes 1993, 42:1297–1302.PubMedCrossRefGoogle Scholar
  7. 7.
    Bhopal R, Unwin N, White M, et al.: Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study. BMJ 1999, 319:215–220.PubMedGoogle Scholar
  8. 8.
    Howard BV, Knowler WC, Vasquez B, et al.: Plasma and lipoprotein cholesterol and triglyceride in the Pima Indian population. Comparison of diabetics and nondiabetics. Arteriosclerosis 1984, 4:462–471.PubMedGoogle Scholar
  9. 9.
    Gray RS, Fabsitz RR, Cowan LD, et al.: Risk factor clustering in the insulin resistance syndrome. The Strong Heart Study. Am J Epidemiol 1998, 148:869–878.PubMedGoogle Scholar
  10. 10.
    Sparks JD, Sparks CE: Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochimica et Biophysica Acta 1994, 1215:9–32.PubMedGoogle Scholar
  11. 11.
    Kendrick JS, Wilkinson J, Cartwright IJ, et al.: Regulation of the assembly and secretion of very low density lipoproteins by the liver. Biol Chem 1998, 379:1033–1040.PubMedGoogle Scholar
  12. 12.
    Taghibiglou C, Carpentier A, Van Iderstine SC, et al.: Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem 2000, 275:8416–8425. An elegant study in a novel animal model of insulin resistance, the fructose-fed Syrian golden hamster, aimed to investigate the mechanisms mediating the overproduction of VLDL in the insulin-resistant state.PubMedCrossRefGoogle Scholar
  13. 13.
    Lin MC, Gordon D, Wetterau JR: Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression. J Lipid Res 1995, 36:1073–1081.PubMedGoogle Scholar
  14. 14.
    Sato R, Miyamoto W, Inoue J, et al.: Sterol regulatory element-binding protein negatively regulates microsomal triglyceride transfer protein gene transcription. J Biol Chem 1999, 274:24714–24720. The authors demonstrated for the first time a novel mechanism by which sterol regulatory element-binding proteins negatively regulate expression of the gene encoding a protein involved in lipid metabolism. MTP mRNA and protein synthesis decline in response to sterol depletion in HepG2 cells.PubMedCrossRefGoogle Scholar
  15. 15.
    Pan M, Liang JS, Fisher EA, Ginsberg HN: The late addition of core lipids to nascent apolipoprotein B100, resulting in the assembly and secretion of triglyceride-rich lipoproteins, is independent of both microsomal triglyceride transfer protein activity and new triglyceride synthesis. J Biol Chem 2002, 277:4413–4421. An original study in which the authors demonstrated that neither MTP nor newly synthesized triglycerides is necessary for the later stages of apo B-100-containing lipoprotein assembly and secretion in hepatoma cell lines, whereas they are critical for the initial targeting of apo B-100 to lipoprotein assembly.PubMedCrossRefGoogle Scholar
  16. 16.
    Banfi C, Mussoni L, Ris P, et al.: Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells. Circ Res 1999, 85:208–217.PubMedGoogle Scholar
  17. 17.
    Banfi C, Eriksson P, Giandomenico G, et al.: Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin: insights into the signaling pathway. Diabetes 2001, 50:1522–1530. The authors analyzed the effects of insulin on PAI-1 biosynthesis in HepG2 cells, demonstrating an increase of PAI-1 gene transcription through interaction of insulin with its receptor. They also outlined the central role of MAP kinase activation in the regulation of PAI-1 induced by insulin.PubMedCrossRefGoogle Scholar
  18. 18.
    Miyashita Y, Shirai K, Itoh Y, et al.: Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy. Diabetes Res Clin Pract 2002, 56:181–187.PubMedCrossRefGoogle Scholar
  19. 19.
    Taskinen MR: Lipoprotein lipase in diabetes. Diabetes Metab Rev 1987, 3:551–570.PubMedCrossRefGoogle Scholar
  20. 20.
    Streicher R, Kotzka J, Muller-Wieland D, et al.: SREBP-1 mediates activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-I. J Biol Chem 1996, 271:7128–7133.PubMedCrossRefGoogle Scholar
  21. 21.
    Malmstrom R, Packard CJ, Watson TD, et al.: Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 1997, 17:1454–1464.PubMedGoogle Scholar
  22. 22.
    Malmstrom R, Packard CJ, Caslake M, et al.: Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. Diabetes 1998, 47:779–787.PubMedCrossRefGoogle Scholar
  23. 23.
    Malmstrom R, Packard CJ, Caslake M, et al.: Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997, 40:454–462.PubMedCrossRefGoogle Scholar
  24. 24.
    Ruotolo G, Micossi P, Galimberti G, et al.: Effects of intraperitoneal versus subcutaneous insulin administration on lipoprotein metabolism in type I diabetes. Metab Clin Exp 1990, 39:598–604.PubMedGoogle Scholar
  25. 25.
    Yu KC, Cooper AD: Postprandial lipoproteins and athero-sclerosis. Front Biosci 2001, 6:D332-D354. A comprehensive review focusing on the metabolic pathway of postprandial lipoproteins, the role of receptors in the efficient removal of chylomicron remnants from the blood circulation, and the potential atherogenic effects of chylomicron remnants on the arterial wall.PubMedCrossRefGoogle Scholar
  26. 26.
    Jeppesen J, Hollenbeck CB, Zhou MY, et al.: Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity, and postprandial lipemia. Arterioscler Thromb Vasc Biol 1995, 15:320–324.PubMedGoogle Scholar
  27. 27.
    Boquist S, Hamsten A, Karpe F, Ruotolo G: Insulin and non-esterified fatty acid relations to alimentary lipaemia and plasma concentrations of postprandial triglyceride-rich lipoproteins in healthy middle-aged men. Diabetologia 2000, 43:185–193.PubMedCrossRefGoogle Scholar
  28. 28.
    Schneeman BO, Kotite L, Todd KM, Havel RJ: Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci U S A 1993, 90:2069–2073.PubMedCrossRefGoogle Scholar
  29. 29.
    Boquist S, Ruotolo G, Tang R, et al.: Alimentary lipemia, post-prandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. Circulation 1999, 100:723–728.PubMedGoogle Scholar
  30. 30.
    Ko KW, Avramoglu RK, McLeod RS, et al.: The insulin-stimulated cell surface presentation of low density lipoprotein receptor-related protein in 3T3-L1 adipocytes is sensitive to phosphatidylinositide 3-kinase inhibition. Biochemistry 2001, 40:752–759.PubMedCrossRefGoogle Scholar
  31. 31.
    Descamps O, Bilheimer D, Herz J: Insulin stimulates receptor-mediated uptake of apoE-enriched lipoproteins and activated alpha 2-macroglobulin in adipocytes. J Biol Chem 1993, 268:974–981.PubMedGoogle Scholar
  32. 32.
    Phillips C, Bennett A, Anderton K, et al.: Intestinal rather than hepatic microsomal triglyceride transfer protein as a cause of postprandial dyslipidemia in diabetes. Metab Clin Exp 2002, 51:847–852.PubMedGoogle Scholar
  33. 33.
    Phillips C, Owens D, Collins P, Tomkin GH: Microsomal triglyceride transfer protein: does insulin resistance play a role in the regulation of chylomicron assembly? Atherosclerosis 2002, 160:355–360.PubMedCrossRefGoogle Scholar
  34. 34.
    Lund-Katz S, Laplaud PM, Phillips MC, Chapman MJ: Apolipo-protein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction. Biochemistry 1998, 37:12867–12874.PubMedCrossRefGoogle Scholar
  35. 35.
    Howard BV, Robbins DC, Sievers ML, et al.: LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. Arterioscler Thromb Vasc Biol 2000, 20:830–835. The Strong Heart Study assessed coronary heart disease and its risk factors in American Indians in Arizona, Oklahoma, and South and North Dakota since 1989. A higher prevalence of small, dense LDL is also present in American Indians with type 2 diabetes. This paper demonstrated that LDL cholesterol is a strong independent predictor of coronary heart disease even in diabetic individuals with low levels of LDL.PubMedGoogle Scholar
  36. 36.
    Haffner SM, Mykkanen L, Valdez RA, et al.: LDL size and subclass pattern in a biethnic population. Arterioscler Thromb 1993, 13:1623–1630.PubMedGoogle Scholar
  37. 37.
    Haffner SM, Morales PA, Stern MP, Gruber MK: Lp(a) concentrations in NIDDM. Diabetes 1992, 41:1267–1272.PubMedCrossRefGoogle Scholar
  38. 38.
    Wang W, Hu D, Lee ET, et al.: Lipoprotein(a) in American Indians is low and not independently associated with cardiovascular disease. The Strong Heart Study. Ann Epidemiol 2002, 12:107–114.PubMedCrossRefGoogle Scholar
  39. 39.
    van’t Hooft FM, Ruotolo G, Boquist S, et al.: Human evidence that the apolipoprotein a-II gene is implicated in visceral fat accumulation and metabolism of triglyceride-rich lipoproteins. Circulation 2001, 104:1223–1228. This paper showed for the first time an association between a functional polymorphism in the human apo A-II promoter and visceral fat accumulation, an important constituent of the metabolic syndrome.Google Scholar
  40. 40.
    Torra IP, Chinetti G, Duval C, et al.: Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipidol 2001, 12:245–254. An excellent review on the multiple roles of PPARs in the evolution of metabolic disorders such as dyslipidemia, obesity, and insulin resistance, predisposing to atherosclerosis.PubMedCrossRefGoogle Scholar
  41. 41.
    Hsueh WA, Law RE: PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 2001, 21:1891–1895.PubMedGoogle Scholar
  42. 42.
    Oliver WR, Jr., Shenk JL, Snaith MR, et al.: A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 2001, 98:5306–5311. In this paper, the authors suggest that PPARδ agonists may be effective drugs to increase reverse cholesterol transport and decrease cardiovascular disease associated with the metabolic syndrome.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Giacomo Ruotolo
    • 1
  • Barbara V. Howard
  1. 1.Penn Medical LaboratoryMedStar Research InstituteWashingtonUSA

Personalised recommendations